Open AccessReactogenicity to COVID-19 vaccination in the United States of America
Author(s) -
Adekunle Sanyaolu,
Aleksandra Marinkovic,
Stephanie Prakash,
Priyank Desai,
Nafees Haider,
Abdus Sattar Abbasi,
Nasima Mehraban,
Isha Jain,
Amarachi Ekeh,
Omar Shazley,
Chuku Okorie,
Verner N. Orish
Publication year - 2022
Publication title -
clinical and experimental vaccine research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.958
H-Index - 11
eISSN - 2287-366X
pISSN - 2287-3651
DOI - 10.7774/cevr.2022.11.1.104
Subject(s) - reactogenicity , medicine , adverse effect , vaccination , chills , adverse event reporting system , covid-19 , pediatrics , emergency medicine , disease , virology , immunology , infectious disease (medical specialty) , immunization , antigen
In the United States, Pfizer-BioNTech, Moderna, and Janssen's coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to analyze passive surveillance data on COVID-19 vaccine adverse reaction in the United States.